Cargando…
Depletion of AADC activity in caudate nucleus and putamen of Parkinson’s disease patients; implications for ongoing AAV2-AADC gene therapy trial
In Parkinson’s disease (PD), aromatic L-amino acid decarboxylase (AADC) is the rate-limiting enzyme in the conversion of L-DOPA (Sinemet) to dopamine (DA). Previous studies in PD animal models demonstrated that lesion of dopaminergic neurons is associated with profound loss of AADC activity in the s...
Autores principales: | Ciesielska, Agnieszka, Samaranch, Lluis, San Sebastian, Waldy, Dickson, Dennis W., Goldman, Samuel, Forsayeth, John, Bankiewicz, Krystof S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293261/ https://www.ncbi.nlm.nih.gov/pubmed/28166239 http://dx.doi.org/10.1371/journal.pone.0169965 |
Ejemplares similares
-
Safety and tolerability of MRI-guided infusion of AAV2-hAADC into the mid-brain of nonhuman primate
por: Sebastian, Waldy San, et al.
Publicado: (2014) -
Carbidopa-Based Modulation of the Functional Effect of the AAV2-hAADC Gene Therapy in 6-OHDA Lesioned Rats
por: Ciesielska, Agnieszka, et al.
Publicado: (2015) -
Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease
por: Hwu, Paul Wuh‐Liang, et al.
Publicado: (2021) -
Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington’s disease
por: Hadaczek, Piotr, et al.
Publicado: (2016) -
Compound Heterozygosis in AADC Deficiency and Its Complex Phenotype in Terms of AADC Protein Population
por: Bisello, Giovanni, et al.
Publicado: (2022)